AzentaAZTA
About: Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
Employees: 3,000
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
8% more capital invested
Capital invested by funds: $2.42B [Q3] → $2.61B (+$199M) [Q4]
4.98% more ownership
Funds ownership: 101.91% [Q3] → 106.89% (+4.98%) [Q4]
6% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 51
0% more funds holding
Funds holding: 305 [Q3] → 306 (+1) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
19% less call options, than puts
Call options by funds: $12.1M | Put options by funds: $15M
26% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 125
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Evercore ISI Group Vijay Kumar 36% 1-year accuracy 17 / 47 met price target | 52%upside $52 | In-Line Maintained | 6 Feb 2025 |
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target | 73%upside $59 | Buy Maintained | 6 Feb 2025 |
Stephens & Co. Jacob Johnson 29% 1-year accuracy 4 / 14 met price target | 76%upside $60 | Overweight Reiterated | 2 Jan 2025 |
Financial journalist opinion
Based on 3 articles about AZTA published over the past 30 days
